15
Participants
Start Date
July 31, 2008
Primary Completion Date
December 31, 2009
Study Completion Date
May 31, 2010
flucinolone acetonide
Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
RECRUITING
Asan Medical Center, Seoul
Lead Sponsor
Samsung Medical Center
OTHER
Seoul National University Hospital
OTHER
Kyunghee University Medical Center
OTHER
Asan Medical Center
OTHER